InnoGI technologies (formerly The TIM Company) is a CRO based in the Netherlands, utilizing its novel in vitro technology TIM to predict oral formulation behavior in vivo. TIM is part of the SurroGut platform for advanced technologies, predicting oral drug behavior to support:
Development and optimization of formulations,
Risk assessments related to bridging between formulations used in different stages of the clinical trial programs or commercial manufacturing.
Selection processes between different drug substance modifications, that is, different salts or solid forms, and/or formulations.
Predicting food interactions.
Predicting dose linearity in exposure because of solubility limitations.
PBB Modelling and
Permeability Studies
With expertise built over 30 years, and trusted relationships with industry, our SurroGut services represent a unique set in your oral drug development process. From formulation ranking, to food-effect, to microbiome studies, we’ll design your study to provide valuable insights into your formulation performance & accelerate your drug development timelines.